Celyad Oncology S.A.
Celyad Oncology S.A. (CYAD) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CYAD · as of Jun 9, 2026
Key Statistics
Explore Celyad Oncology S.A. Data
cyad stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 60.0%
Competitors & Peers
cyad competitorsCYAD
ATON
AXLA
GLS
HURA
IMNNStock Performance
Full HistoryAbout Celyad Oncology S.A.
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The c…
what is celyad oncology s.a. · cyad stock overview · celyad oncology s.a. company profile · who is celyad oncology s.a. ceo · cyad NASDAQ · celyad oncology s.a. headquarters · celyad oncology s.a. business segments
About Stock Overview & Key Data
Celyad Oncology S.A. (CYAD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 19, 2015. As of the latest trading session, CYAD stock price is $0.47, with a market capitalization of $14.2M. The stock has returned -74.18% over the past 12 months and -6.00% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Celyad Oncology S.A. stock is Buy, with an average 12-month price target of $—. In fiscal year 2024, Celyad Oncology S.A. reported revenue of $186000.00 and net income of -$5.8M. For detailed data — including Celyad Oncology S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Celyad Oncology S.A. (CYAD) stock price is $0.47. The stock is traded on NASDAQ under the ticker symbol CYAD. The 52-week range is $0.15 – $3.07.